Oligonucelotides and mRNA Therapeutics 2023 (OPT)

Back

FORCE™ Platform for Delivery of Oligonucleotides for the Treatment of DM1 and DMD: Moving from Bench to Clinic with DYNE-101 and DYNE-251 (presentation)

View

©2026 Dyne Therapeutics, Inc. All rights reserved MED-00978. Date of preparation: July 2026.